Nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
== Drug interactions == Both dalfopristin and quinupristin are extensively hepatically metabolized, excreted from the feces, and serve as an inhibitor of cytochrome P450 (CYP) 3A4 enzyme pathway. Caution should be taken with concommitent use with drugs metabolized by the CYP3A4 pathway. Concomitant use of quinupristin/dalfopristin with cyclosporine for 2–5 days has shown to result in a two-fold increase in cyclosporine levels. No adverse effects have been seen in patients with hepatic impairment and no recommendations by the manufacturer have been made for dose reduction of quinupristin/dalfopristin in this patient population.
=== Basement membrane zone === In the skin the basement membrane that separates, and connects the epidermis and the underlying dermis is part of a complex and specialized structure called the basement membrane zone (BMZ). The BMZ has four distinct layers – the basal cell layer, the lamina lucida, the lamina densa, and the sublaminal densa, and has many functions. Tiny microfilaments called tonofilaments cross the basal cell layer, and extend to the epidermal part of the hemidesmosome. Laminins and other adherence proteins are located in the lamina lucida. The lamina densa is mostly composed of a type IV collagen scaffold. Anchoring fibrils and microfilaments extend and blend with the elastic fibrillary system of the dermis. The components of the BMZ form a complex, functional network that extends from the basal epidermal keratinocytes and their hemidesmosomes, and include anchoring fibrils from the lamina densa, into the extracellular matrix (ECM) of the dermis. In the ECM the anchoring fibrils appear as cross-striated fibrous masses. There are also focal adhesion complexes on the outer cell membrane that bind the cytoskeleton to cell-matrix adhesions.
== Genetics == Biallelic pathogenic variants in GAMT are associated with guanidinoacetate methyltransferase deficiency. Over 70 variants have been reported in the GAMT gene. This gene codes for the enzyme guanidinoacetate methyltransferase (GAMT), which participates in the two-step synthesis of the compound creatine from amino acids glycine, arginine and methionine. Specifically, GAMT controls the second step of the sequence, in which creatine is produced from another compound called guanidinoacetate. GAA is toxic, and because GAMT patients lack the enzyme used to convert GAA to creatine, a build-up of GAA occurs in the brain and other tissues. This accumulation of GAA is thought to cause the more severe symptoms of GATM deficiency. The effects of GAMT deficiency are most severe in organs and tissues that require large amounts of energy, such as the brain and muscles. This disorder is inherited in an autosomal recessive manner, which means the causative gene is located on an autosome, and two defective copies of the gene – one from each parent – are required to inherit the disorder. The parents both carry one pathogenic variant; however, they are not affected by the disorder. As carriers, the residual activity of approximately 50% is enough to avoid clinical complications. Any siblings of an GAMT deficient individual have a 25% chance of also being GAMT deficient, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
The second safeguard clause was a commitment that nothing should be done which might prejudice the rights of the Jewish communities in other countries outside of Palestine. The original drafts of Rothschild, Balfour, and Milner did not include this safeguard, which was drafted together with the preceding safeguard in early October, in order to reflect opposition from influential members of the Anglo-Jewish community. Lord Rothschild took exception to the proviso on the basis that it presupposed the possibility of a danger to non-Zionists, which he denied. The Conjoint Foreign Committee of the Board of Deputies of British Jews and the Anglo-Jewish Association had published a letter in The Times on 24 May 1917 entitled Views of Anglo-Jewry, signed by the two organisations' presidents, David Lindo Alexander and Claude Montefiore, stating their view that: "the establishment of a Jewish nationality in Palestine, founded on this theory of homelessness, must have the effect throughout the world of stamping the Jews as strangers in their native lands, and of undermining their hard-won position as citizens and nationals of these lands." This was followed in late August by Edwin Montagu, an influential anti-Zionist Jew and Secretary of State for India, and the only Jewish member of the British Cabinet, who wrote in a Cabinet memorandum that: "The policy of His Majesty's Government is anti-Semitic in result and will prove a rallying ground for anti-Semites in every country of the world."
Sources: en.wikipedia.org
Acetamide (systematic name: ethanamide) is an organic compound with the formula CH3CONH2. It is an amide derived from ammonia and acetic acid. It finds some use as a plasticizer and as an industrial solvent. The related compound N,N-dimethylacetamide (DMA) is more widely used, but it is not prepared from acetamide. Acetamide can be considered an intermediate between acetone, which has two methyl (CH3) groups either side of the carbonyl (CO), and urea which has two amide (NH2) groups in those locations. Acetamide is also a naturally occurring mineral with the IMA symbol: Ace.
=== Monitoring and detection === The goal of most monitoring and detection processes is the rapid detection of harmful microorganisms with minimal interruption to the processing of food products. An example of a detection mechanism that relies heavily on biological processes is usage of chromogenic microbiological media.
=== Support team === Mission Director and Flight Director - Red Team: Christopher C. Kraft, Jr. Flight Director - Blue Team: John D. Hodge Flight Director - White Team: Eugene F. Kranz CAPCOMs: Gus Grissom, Roger B. Chaffee, and Eugene Cernan Worldwide support and recovery team: 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships.
Sources: en.wikipedia.org
==== Neuroregeneration ==== Regenerative strategies within the central nervous system (CNS) and peripheral nervous system (PNS) address severe impairments caused by spinal cord injuries, ischemic strokes, and neurodegenerative disorders such as Parkinson's disease. The therapeutic microenvironment of the adult brain and spinal cord is highly inhibitory to axon growth due to the formation of glial scars and chondroitin sulfate proteoglycans. Neuroregeneration research utilizes injectable hydrogels, shear-thinning biomaterials, and electrospun guidance conduits to physically bridge lesion cavities. These scaffolds are frequently loaded with neural stem cells (NSCs), neurotrophic growth factors, or enzyme-releasing agents to neutralize inhibitory molecular cues, support survival of transplanted dopaminergic or motor neurons, and provide a permissive physical framework for directed axonal elongation and synaptogenesis.
Additionally, Paul Bettany was the first actor to portray two main characters within the universe, voicing Tony Stark's artificial intelligence J.A.R.V.I.S. and portraying Vision. James D'Arcy was the first actor to reprise their role as a character introduced in an MCU television series in an MCU film, portraying Edwin Jarvis—the human inspiration for J.A.R.V.I.S.—in the series Agent Carter (2015–16) and Avengers: Endgame. J. K. Simmons became the first actor to reprise a non-MCU role in the MCU when he appeared as J. Jonah Jameson (a role he played in Sam Raimi's Spider-Man trilogy from 2002 to 2007) in Spider-Man: Far From Home. Prior to his death in 2018, Stan Lee, the creator or co-creator of many of the characters adapted in the MCU, made cameo appearances in all of the feature films and television series except Inhumans. In Iron Fist, it is revealed his on-set photograph cameo in the Marvel Netflix series is as NYPD Captain Irving Forbush. His cameo in Guardians of the Galaxy Vol. 2 sees Lee appearing as an informant to the Watchers, discussing previous adventures that include Lee's cameos in other MCU films; he specifically mentions his time as a FedEx delivery man, referring to Lee's cameo in Captain America: Civil War. This acknowledged the fan theory that Lee may be portraying the same character in all his cameos, with writer and director James Gunn noting that commentators believed Lee was portraying the character Uatu the Watcher and "that all of these cameos are part of him being a Watcher.
ALK-negative ALCL tumor cells show products made by chimeric genes: DUSP22-IRF4 (many of which are fused at particular site and termed DUSP22-FRA7H) in 30% of the cases; TP63-TBL1XR1 in 8% of cases; and NFKB2-ROS1, NCOR2-ROS1, NFKB2-TYK2, or PABPC4-TYK2 in rare cases. They also show mutations in the JAK1 and/or STAT3 genes in 18% of cases; the MSC gene in 15% of cases, and the NOTCH1 gene in 15% of cases. About 24% of cases have a truncated ERBB4 gene. DUSP22 gene rearrangements have been associated with favorable outcomes in ALK-negative ALCL while TP63 gene arrangements are often associated with a poorer prognosis in various cancers. ALK-negative ALCL cells overexpress overactive STAT3 in 47% of cases and JAK1 in many cases. Many of these gene abnormalities appear to contribute to the development of ALK-negative ALCL.
== Experimental chemistry == Unambiguous determination of the chemical characteristics of roentgenium has yet to have been established due to the low yields of reactions that produce roentgenium isotopes. For chemical studies to be carried out on a transactinide, at least four atoms must be produced, the half-life of the isotope used must be at least 1 second, and the rate of production must be at least one atom per week. Even though the half-life of 282Rg, the most stable confirmed roentgenium isotope, is 100 seconds, long enough to perform chemical studies, another obstacle is the need to increase the rate of production of roentgenium isotopes and allow experiments to carry on for weeks or months so that statistically significant results can be obtained. Separation and detection must be carried out continuously to separate out the roentgenium isotopes and allow automated systems to experiment on the gas-phase and solution chemistry of roentgenium, as the yields for heavier elements are predicted to be smaller than those for lighter elements. However, the experimental chemistry of roentgenium has not received as much attention as that of the heavier elements from copernicium to livermorium, despite early interest in theoretical predictions due to relativistic effects on the ns subshell in group 11 reaching a maximum at roentgenium.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.